首页 > 最新文献

JAMA Oncology最新文献

英文 中文
Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer—Long-Term Results of a Randomized Clinical Trial 吉非替尼与吉非替尼加培美曲塞和卡铂化疗治疗表皮生长因子受体变异型肺癌--随机临床试验的长期结果
IF 28.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-04-25 DOI: 10.1001/jamaoncol.2024.0584
Vanita Noronha, Vijay Patil, Nandini Menon, Minit Shah, Anuradha Chougule, Zoya Peelay, Kumar Prabhash
This randomized clinical trial examines whether adding chemotherapy with pemetrexed and carboplatin to gefitinib improves survival among patients with epidermal growth factor receptor (EGFR)–variant non–small cell lung cancer.
这项随机临床试验探讨了在吉非替尼基础上加用培美曲塞和卡铂化疗是否能提高表皮生长因子受体(EGFR)变异型非小细胞肺癌患者的生存率。
{"title":"Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer—Long-Term Results of a Randomized Clinical Trial","authors":"Vanita Noronha, Vijay Patil, Nandini Menon, Minit Shah, Anuradha Chougule, Zoya Peelay, Kumar Prabhash","doi":"10.1001/jamaoncol.2024.0584","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.0584","url":null,"abstract":"This randomized clinical trial examines whether adding chemotherapy with pemetrexed and carboplatin to gefitinib improves survival among patients with epidermal growth factor receptor (<jats:italic>EGFR</jats:italic>)–variant non–small cell lung cancer.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"51 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140649107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia 异体 CD19/CD22 CAR T 细胞疗法治疗 B 细胞急性淋巴细胞白血病
IF 28.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-04-18 DOI: 10.1001/jamaoncol.2024.0473
Laurent Phely, Luca Hensen, Christoph Faul, Christer Alexander Ruff, Dina Schneider, Wolfgang Andreas Bethge, Claudia Lengerke
This case series reports durable remissions in 2 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with allogeneic bispecific CD19/CD22-targeting chimeric antigen receptor T cells.
本系列病例报告了两名接受异体双特异性 CD19/CD22 靶向嵌合抗原受体 T 细胞治疗的复发/难治性 B 细胞急性淋巴细胞白血病患者的持久缓解情况。
{"title":"Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia","authors":"Laurent Phely, Luca Hensen, Christoph Faul, Christer Alexander Ruff, Dina Schneider, Wolfgang Andreas Bethge, Claudia Lengerke","doi":"10.1001/jamaoncol.2024.0473","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.0473","url":null,"abstract":"This case series reports durable remissions in 2 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with allogeneic bispecific CD19/CD22-targeting chimeric antigen receptor T cells.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"89 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140620204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy 嵌合抗原受体 T 细胞疗法后的 T 细胞恶性肿瘤
IF 28.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-04-18 DOI: 10.1001/jamaoncol.2024.0662
Ryan Storgard, Kai Rejeski, Miguel-Angel Perales, Adam Goldman, Roni Shouval
This cohort study assesses the increase in second primary malignant neoplasms and T-cell malignant neoplasm cases associated with chimeric antigen receptor–T cells.
这项队列研究评估了与嵌合抗原受体-T 细胞相关的第二原发性恶性肿瘤和 T 细胞恶性肿瘤病例的增加情况。
{"title":"T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy","authors":"Ryan Storgard, Kai Rejeski, Miguel-Angel Perales, Adam Goldman, Roni Shouval","doi":"10.1001/jamaoncol.2024.0662","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.0662","url":null,"abstract":"This cohort study assesses the increase in second primary malignant neoplasms and T-cell malignant neoplasm cases associated with chimeric antigen receptor–T cells.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"30 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140620352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Policy Priorities in Cancer Care for Transgender People 变性人癌症护理的政策重点
IF 28.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-04-18 DOI: 10.1001/jamaoncol.2024.0451
Alicia C. Smart, Michael J. Yunes, Karen M. Winkfield
This Viewpoint calls for health care systems, oncologists, and staff to prioritize and adopt policies that are inclusive and respectful of transgender patients with cancer.
本观点呼吁医疗保健系统、肿瘤学家和工作人员优先考虑并采取包容和尊重癌症变性患者的政策。
{"title":"Policy Priorities in Cancer Care for Transgender People","authors":"Alicia C. Smart, Michael J. Yunes, Karen M. Winkfield","doi":"10.1001/jamaoncol.2024.0451","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.0451","url":null,"abstract":"This Viewpoint calls for health care systems, oncologists, and staff to prioritize and adopt policies that are inclusive and respectful of transgender patients with cancer.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"20 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140620545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adherence to American Cancer Society Nutrition and Physical Activity Guidelines Among Cancer Survivors 癌症幸存者遵守美国癌症协会营养和体育活动指南的情况
IF 28.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-04-18 DOI: 10.1001/jamaoncol.2024.0470
Carter Baughman, Kathryn Norman, Kenneth Mukamal
ImportanceThe American Cancer Society’s (ACS’s) nutrition and physical activity guidelines are intended to reduce morbidity and mortality among cancer survivors, but to our knowledge, adherence to these guidelines has not been systematically quantified.ObjectiveTo evaluate adherence to and factors associated with adherence to lifestyle modification guidelines among cancer survivors.Design, Setting, and ParticipantsThis cross-sectional study used data from the Behavioral Risk Factor Surveillance System using survey administration years 2017 (surveys completed between January 2017 and March 2018), 2019 (surveys completed between January 2019 and December 2019), and 2021 (surveys completed between January 2021 and February 2022). The study included people who had completed cancer treatment at any point prior to the given survey administration year. Data were analyzed from September 19, 2022, to December 12, 2022.Main Outcomes and MeasuresThe primary outcome was adherence to current ACS guidelines for physical activity, body mass index, alcohol use, and fruit and vegetable intake. Factors associated with adherence rates to the guidelines, including age, sex, race and ethnicity, location, and educational level, were evaluated using linear regression. Complex survey weights were used.ResultsA total of 10 020 respondents (57% female; mean [SE] age, 64.2 [0.3] years) reported completion of cancer treatment, representing 2.7 million US individuals over 3 years. Of these respondents, 9121 completed questionnaires for all 4 metrics measured. A total of 72% (95% CI, 71%-74%) of cancer survivors met criteria for adequate physical activity, 68% (95% CI, 66%-69%) did not have obesity, 12% (95% CI, 11%-13%) ate adequate fruits and vegetables, and 50% (95% CI, 49%-52%) did not drink alcohol. In total, 4% (95% CI, 3%-4%) of cancer survivors adhered to all 4 guidelines, with the mean number of guidelines met being 2.0 (95% CI, 2.0-2.1). Factors associated with greater adherence included female sex, older age, Black race, higher educational level, and residence in Western US states.Conclusions and RelevanceIn this cross-sectional study, 4% of cancer survivors fully adhered to current ACS recommendations. Improved understanding of guideline adherence and its determinants may guide oncologists and general internists in providing recommendations for their patients who have completed cancer treatments.
重要性美国癌症协会(ACS)的营养和体育锻炼指南旨在降低癌症幸存者的发病率和死亡率,但据我们所知,这些指南的遵守情况尚未被系统地量化。目的评估癌症幸存者对生活方式调整指南的遵守情况及其相关因素。设计、地点和参与者这项横断面研究使用了行为风险因素监测系统的数据,调查管理年份为 2017 年(调查在 2017 年 1 月至 2018 年 3 月期间完成)、2019 年(调查在 2019 年 1 月至 2019 年 12 月期间完成)和 2021 年(调查在 2021 年 1 月至 2022 年 2 月期间完成)。研究对象包括在特定调查管理年之前任何时间点完成癌症治疗的人。主要结果和测量指标主要结果是遵守 ACS 关于体育锻炼、体重指数、饮酒以及水果和蔬菜摄入量的现行指南。采用线性回归法评估了与指南遵守率相关的因素,包括年龄、性别、种族和民族、地区和教育水平。结果 共有 10 020 名受访者(57% 为女性;平均 [SE] 年龄为 64.2 [0.3] 岁)报告已完成癌症治疗,代表 3 年内 270 万美国人。在这些受访者中,有 9121 人完成了所有 4 项指标的问卷调查。共有 72% (95% CI, 71%-74%) 的癌症幸存者符合适当体育锻炼的标准,68% (95% CI, 66%-69%) 没有肥胖,12% (95% CI, 11%-13%) 吃足够的水果和蔬菜,50% (95% CI, 49%-52%) 不喝酒。总共有 4% (95% CI,3%-4%)的癌症幸存者遵守了所有 4 项指南,遵守指南的平均数量为 2.0(95% CI,2.0-2.1)。与更严格遵守指南相关的因素包括女性、年龄较大、黑人、教育程度较高以及居住在美国西部各州。加深对指南遵守情况及其决定因素的了解可指导肿瘤学家和普通内科医生为已完成癌症治疗的患者提供建议。
{"title":"Adherence to American Cancer Society Nutrition and Physical Activity Guidelines Among Cancer Survivors","authors":"Carter Baughman, Kathryn Norman, Kenneth Mukamal","doi":"10.1001/jamaoncol.2024.0470","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.0470","url":null,"abstract":"ImportanceThe American Cancer Society’s (ACS’s) nutrition and physical activity guidelines are intended to reduce morbidity and mortality among cancer survivors, but to our knowledge, adherence to these guidelines has not been systematically quantified.ObjectiveTo evaluate adherence to and factors associated with adherence to lifestyle modification guidelines among cancer survivors.Design, Setting, and ParticipantsThis cross-sectional study used data from the Behavioral Risk Factor Surveillance System using survey administration years 2017 (surveys completed between January 2017 and March 2018), 2019 (surveys completed between January 2019 and December 2019), and 2021 (surveys completed between January 2021 and February 2022). The study included people who had completed cancer treatment at any point prior to the given survey administration year. Data were analyzed from September 19, 2022, to December 12, 2022.Main Outcomes and MeasuresThe primary outcome was adherence to current ACS guidelines for physical activity, body mass index, alcohol use, and fruit and vegetable intake. Factors associated with adherence rates to the guidelines, including age, sex, race and ethnicity, location, and educational level, were evaluated using linear regression. Complex survey weights were used.ResultsA total of 10 020 respondents (57% female; mean [SE] age, 64.2 [0.3] years) reported completion of cancer treatment, representing 2.7 million US individuals over 3 years. Of these respondents, 9121 completed questionnaires for all 4 metrics measured. A total of 72% (95% CI, 71%-74%) of cancer survivors met criteria for adequate physical activity, 68% (95% CI, 66%-69%) did not have obesity, 12% (95% CI, 11%-13%) ate adequate fruits and vegetables, and 50% (95% CI, 49%-52%) did not drink alcohol. In total, 4% (95% CI, 3%-4%) of cancer survivors adhered to all 4 guidelines, with the mean number of guidelines met being 2.0 (95% CI, 2.0-2.1). Factors associated with greater adherence included female sex, older age, Black race, higher educational level, and residence in Western US states.Conclusions and RelevanceIn this cross-sectional study, 4% of cancer survivors fully adhered to current ACS recommendations. Improved understanding of guideline adherence and its determinants may guide oncologists and general internists in providing recommendations for their patients who have completed cancer treatments.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"100 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140620212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-Reported Outcomes as a Recruitment Strategy for Clinical Trial Enrollment 将患者报告结果作为临床试验注册的一种招募策略
IF 28.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-04-11 DOI: 10.1001/jamaoncol.2024.0280
Nicholas P. Verdini, Karolina L. Bryl, Raymond E. Baser, Kaitlyn Lapen, Jun J. Mao, Erin F. Gillespie
ImportanceClinical trials are critical for progress in oncology; however, only 5% of the adult cancer population participates. Harnessing data that are routinely collected (ie, electronic patient-reported outcomes [ePROs]) may serve as a method to promote trial enrollment.ObjectiveTo evaluate if an ePRO-prompted recruitment strategy is associated with increased clinical trial enrollment.Design, Setting, and ParticipantsA randomized substudy was conducted from September 2022 to March 2023 at a multisite tertiary cancer center as part of an ongoing clinical trial that was testing a symptom-intervention for cancer-related fatigue. Patients with breast cancer who were undergoing radiotherapy who completed at least 1 ePRO questionnaire during the study period were included. Physician-level cluster randomization assigned fatigue-eligible patients to either receive a portal message invitation to a symptom-intervention trial or standard of care (SOC; physician-based referral).ExposureePRO questionnaires distributed in routine practice were queried weekly and screened for moderate or greater fatigue, the principle inclusion criterion for the primary trial. To assess the association of the portal message source with response and enrollment, every other patient received a message from the primary radiation oncology team or the referral service.Main Outcomes and MeasuresClinical trial response/referral and enrollment.ResultsA total of 1041 patients completed ePRO questionnaires, of whom 394 (38%; 53 Asian [13.6%], 43 Black [11.0%], 29 Hispanic [7.4%], and 262 White individuals [66.5%]; median [IQR] age, 55 [47-65] years) endorsed moderate or greater fatigue while receiving treatment. A total of 210 patients (53.3%) were assigned to receive a portal message and 184 (46.7%) patients, SOC. In the portal message group, 73 patients (35%) responded and 41 (20%) enrolled compared with 1 patient (0.5%) referred and 0 enrolled in the SOC group (P &amp;lt; .001). The response rate to portal messages favored the referral service vs the primary radiation oncology service (44% vs 26%; P = .01), but there was no significant difference in enrollments.Conclusions and RelevanceThe study results suggest that use of routine care ePROs was associated with greater enrollment in a symptom-intervention trial compared with physician-based referral. Messaging directly from the referral service may support enrollment and help reduce oncology physician-level barriers to trial enrollment for studies testing symptom interventions.
重要性临床试验对肿瘤学的发展至关重要;然而,只有5%的成年癌症患者参与了临床试验。利用常规收集的数据(即电子患者报告结果 [ePRO])可作为促进试验入组的一种方法。目标评估电子患者报告结果提示的招募策略是否与临床试验入组人数的增加有关。设计、设置和参与者2022年9月至2023年3月,在一家多地点三级癌症中心进行了一项随机子研究,作为正在进行的临床试验的一部分,该试验正在测试一种针对癌症相关疲劳的症状干预措施。研究对象包括正在接受放疗的乳腺癌患者,这些患者在研究期间至少填写了一份 ePRO 问卷。在常规治疗中发放的暴露ePRO问卷每周都会被查询并筛查出中度或更严重的疲劳,这也是主要试验的主要纳入标准。为了评估门户网站信息来源与响应和注册的关联性,每一位其他患者都收到了来自初级放射肿瘤团队或转诊服务机构的信息。主要结果和测量指标临床试验响应/转诊和注册。结果共有 1041 名患者完成了 ePRO 问卷调查,其中 394 名患者(38%;53 名亚裔[13.6%]、43 名黑人[11.0%]、29 名西班牙裔[7.4%]和 262 名白人[66.5%];中位[IQR]年龄 55 [47-65] 岁)在接受治疗期间表示有中度或更严重的疲劳感。共有 210 名患者(53.3%)被指定接受门户信息,184 名患者(46.7%)被指定接受 SOC。在门户网站信息组中,73 名患者(35%)做出了回应,41 名患者(20%)加入了该组,而在 SOC 组中,1 名患者(0.5%)被转介,0 名患者加入了该组(P &amp;lt; .001)。对门户网站信息的回复率有利于转诊服务,而不利于肿瘤放射学初级服务(44% vs 26%; P = .01),但注册人数没有显著差异。研究结果表明,与医生转诊相比,使用常规护理 ePRO 与更多人加入症状干预试验有关。转诊服务直接发送的信息可能会支持试验入组,并有助于减少肿瘤医生层面对症状干预试验入组的障碍。
{"title":"Patient-Reported Outcomes as a Recruitment Strategy for Clinical Trial Enrollment","authors":"Nicholas P. Verdini, Karolina L. Bryl, Raymond E. Baser, Kaitlyn Lapen, Jun J. Mao, Erin F. Gillespie","doi":"10.1001/jamaoncol.2024.0280","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.0280","url":null,"abstract":"ImportanceClinical trials are critical for progress in oncology; however, only 5% of the adult cancer population participates. Harnessing data that are routinely collected (ie, electronic patient-reported outcomes [ePROs]) may serve as a method to promote trial enrollment.ObjectiveTo evaluate if an ePRO-prompted recruitment strategy is associated with increased clinical trial enrollment.Design, Setting, and ParticipantsA randomized substudy was conducted from September 2022 to March 2023 at a multisite tertiary cancer center as part of an ongoing clinical trial that was testing a symptom-intervention for cancer-related fatigue. Patients with breast cancer who were undergoing radiotherapy who completed at least 1 ePRO questionnaire during the study period were included. Physician-level cluster randomization assigned fatigue-eligible patients to either receive a portal message invitation to a symptom-intervention trial or standard of care (SOC; physician-based referral).ExposureePRO questionnaires distributed in routine practice were queried weekly and screened for moderate or greater fatigue, the principle inclusion criterion for the primary trial. To assess the association of the portal message source with response and enrollment, every other patient received a message from the primary radiation oncology team or the referral service.Main Outcomes and MeasuresClinical trial response/referral and enrollment.ResultsA total of 1041 patients completed ePRO questionnaires, of whom 394 (38%; 53 Asian [13.6%], 43 Black [11.0%], 29 Hispanic [7.4%], and 262 White individuals [66.5%]; median [IQR] age, 55 [47-65] years) endorsed moderate or greater fatigue while receiving treatment. A total of 210 patients (53.3%) were assigned to receive a portal message and 184 (46.7%) patients, SOC. In the portal message group, 73 patients (35%) responded and 41 (20%) enrolled compared with 1 patient (0.5%) referred and 0 enrolled in the SOC group (<jats:italic>P</jats:italic> &amp;amp;lt; .001). The response rate to portal messages favored the referral service vs the primary radiation oncology service (44% vs 26%; <jats:italic>P</jats:italic> = .01), but there was no significant difference in enrollments.Conclusions and RelevanceThe study results suggest that use of routine care ePROs was associated with greater enrollment in a symptom-intervention trial compared with physician-based referral. Messaging directly from the referral service may support enrollment and help reduce oncology physician-level barriers to trial enrollment for studies testing symptom interventions.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"33 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140547696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Second Primary Breast Cancer in Young Breast Cancer Survivors 年轻乳腺癌幸存者的第二原发性乳腺癌
IF 28.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-04-11 DOI: 10.1001/jamaoncol.2024.0286
Kristen D. Brantley, Shoshana M. Rosenberg, Laura C. Collins, Kathryn J. Ruddy, Rulla M. Tamimi, Lidia Schapira, Virginia F. Borges, Ellen Warner, Steven E. Come, Yue Zheng, Gregory J. Kirkner, Craig Snow, Eric P. Winer, Ann H. Partridge
ImportanceAmong women diagnosed with primary breast cancer (BC) at or younger than age 40 years, prior data suggest that their risk of a second primary BC (SPBC) is higher than that of women who are older when they develop a first primary BC.ObjectiveTo estimate cumulative incidence and characterize risk factors of SPBC among young patients with BC.Design, Setting, and ParticipantsParticipants were enrolled in the Young Women’s Breast Cancer Study, a prospective study of 1297 women aged 40 years or younger who were diagnosed with stage 0 to III BC from August 2006 to June 2015. Demographic, genetic testing, treatment, and outcome data were collected by patient surveys and medical record review. A time-to-event analysis was used to account for competing risks when determining cumulative incidence of SPBC, and Fine-Gray subdistribution hazard models were used to evaluate associations between clinical factors and SPBC risk. Data were analyzed from January to May 2023.Main Outcomes and MeasuresThe 5- and 10- year cumulative incidence of SPBC.ResultsIn all, 685 women with stage 0 to III BC (mean [SD] age at primary BC diagnosis, 36 [4] years) who underwent unilateral mastectomy or lumpectomy as the primary surgery for BC were included in the analysis. Over a median (IQR) follow-up of 10.0 (7.4-12.1) years, 17 patients (2.5%) developed an SPBC; 2 of these patients had cancer in the ipsilateral breast after lumpectomy. The median (IQR) time from primary BC diagnosis to SPBC was 4.2 (3.3-5.6) years. Among 577 women who underwent genetic testing, the 10-year risk of SPBC was 2.2% for women who did not carry a pathogenic variant (12 of 544) and 8.9% for carriers of a pathogenic variant (3 of 33). In multivariate analyses, the risk of SPBC was higher among PV carriers vs noncarriers (subdistribution hazard ratio [sHR], 5.27; 95% CI, 1.43-19.43) and women with primary in situ BC vs invasive BC (sHR, 5.61; 95% CI, 1.52-20.70).ConclusionsFindings of this cohort study suggest that young BC survivors without a germline pathogenic variant have a low risk of developing a SPBC in the first 10 years after diagnosis. Findings from germline genetic testing may inform treatment decision-making and follow-up care considerations in this population.
重要性在40岁或40岁以下确诊为原发性乳腺癌(BC)的女性中,以往的数据表明她们发生第二次原发性乳腺癌(SPBC)的风险高于年龄较大的女性。目标估计年轻BC患者中SPBC的累积发病率并确定其风险因素的特征。通过患者调查和病历审查收集了人口统计学、基因检测、治疗和结果数据。在确定SPBC累积发病率时,采用了时间到事件分析法来考虑竞争风险,并使用Fine-Gray子分布危险模型来评估临床因素与SPBC风险之间的关联。主要结果和测量指标SPBC的5年和10年累积发病率。结果共有685名患0至III期BC(原发性BC诊断时的平均[标度]年龄为36[4]岁)、接受单侧乳房切除术或肿块切除术作为原发性BC手术的女性纳入分析。在中位(IQR)为10.0(7.4-12.1)年的随访期间,有17名患者(2.5%)出现了SPBC;其中2名患者在接受肿块切除术后,同侧乳房也出现了癌症。从原发性乳腺癌诊断到 SPBC 的中位(IQR)时间为 4.2(3.3-5.6)年。在接受基因检测的 577 名女性中,未携带致病变体的女性 10 年 SPBC 风险为 2.2%(544 人中有 12 人),致病变体携带者 10 年 SPBC 风险为 8.9%(33 人中有 3 人)。在多变量分析中,PV 携带者与非携带者(亚分布危险比 [sHR],5.27;95% CI,1.43-19.43)以及原发性原位 BC 与浸润性 BC 妇女(sHR,5.61;95% CI,1.52-20.70)的 SPBC 风险更高。种系基因检测结果可为该人群的治疗决策和后续护理提供参考。
{"title":"Second Primary Breast Cancer in Young Breast Cancer Survivors","authors":"Kristen D. Brantley, Shoshana M. Rosenberg, Laura C. Collins, Kathryn J. Ruddy, Rulla M. Tamimi, Lidia Schapira, Virginia F. Borges, Ellen Warner, Steven E. Come, Yue Zheng, Gregory J. Kirkner, Craig Snow, Eric P. Winer, Ann H. Partridge","doi":"10.1001/jamaoncol.2024.0286","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.0286","url":null,"abstract":"ImportanceAmong women diagnosed with primary breast cancer (BC) at or younger than age 40 years, prior data suggest that their risk of a second primary BC (SPBC) is higher than that of women who are older when they develop a first primary BC.ObjectiveTo estimate cumulative incidence and characterize risk factors of SPBC among young patients with BC.Design, Setting, and ParticipantsParticipants were enrolled in the Young Women’s Breast Cancer Study, a prospective study of 1297 women aged 40 years or younger who were diagnosed with stage 0 to III BC from August 2006 to June 2015. Demographic, genetic testing, treatment, and outcome data were collected by patient surveys and medical record review. A time-to-event analysis was used to account for competing risks when determining cumulative incidence of SPBC, and Fine-Gray subdistribution hazard models were used to evaluate associations between clinical factors and SPBC risk. Data were analyzed from January to May 2023.Main Outcomes and MeasuresThe 5- and 10- year cumulative incidence of SPBC.ResultsIn all, 685 women with stage 0 to III BC (mean [SD] age at primary BC diagnosis, 36 [4] years) who underwent unilateral mastectomy or lumpectomy as the primary surgery for BC were included in the analysis. Over a median (IQR) follow-up of 10.0 (7.4-12.1) years, 17 patients (2.5%) developed an SPBC; 2 of these patients had cancer in the ipsilateral breast after lumpectomy. The median (IQR) time from primary BC diagnosis to SPBC was 4.2 (3.3-5.6) years. Among 577 women who underwent genetic testing, the 10-year risk of SPBC was 2.2% for women who did not carry a pathogenic variant (12 of 544) and 8.9% for carriers of a pathogenic variant (3 of 33). In multivariate analyses, the risk of SPBC was higher among PV carriers vs noncarriers (subdistribution hazard ratio [sHR], 5.27; 95% CI, 1.43-19.43) and women with primary in situ BC vs invasive BC (sHR, 5.61; 95% CI, 1.52-20.70).ConclusionsFindings of this cohort study suggest that young BC survivors without a germline pathogenic variant have a low risk of developing a SPBC in the first 10 years after diagnosis. Findings from germline genetic testing may inform treatment decision-making and follow-up care considerations in this population.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"108 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140547616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer 美国镭学会《不可切除的局部晚期非小细胞肺癌的适当使用标准
IF 28.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-04-11 DOI: 10.1001/jamaoncol.2024.0294
George Rodrigues, Kristin A. Higgins, Andreas Rimner, Arya Amini, Joe Y. Chang, Stephen G. Chun, Jessica Donington, Martin J. Edelman, Matthew A. Gubens, Puneeth Iyengar, Benjamin Movsas, Matthew S. Ning, Henry S. Park, Andrea Wolf, Charles B. Simone
ImportanceThe treatment of locally advanced non–small cell lung cancer (LA-NSCLC) has been informed by more than 5 decades of clinical trials and other relevant literature. However, controversies remain regarding the application of various radiation and systemic therapies in commonly encountered clinical scenarios.ObjectiveTo develop case-referenced consensus and evidence-based guidelines to inform clinical practice in unresectable LA-NSCLC.Evidence ReviewThe American Radium Society (ARS) Appropriate Use Criteria (AUC) Thoracic Committee guideline is an evidence-based consensus document assessing various clinical scenarios associated with LA-NSCLC. A systematic review of the literature with evidence ratings was conducted to inform the appropriateness of treatment recommendations by the ARS AUC Thoracic Committee for the management of unresectable LA-NSCLC.FindingsTreatment appropriateness of a variety of LA-NSCLC scenarios was assessed by a consensus-based modified Delphi approach using a range of 3 points to 9 points to denote consensus agreement. Committee recommendations were vetted by the ARS AUC Executive Committee and a 2-week public comment period before official approval and adoption. Standard of care management of good prognosis LA-NSCLC consists of combined concurrent radical (60-70 Gy) platinum-based chemoradiation followed by consolidation durvalumab immunotherapy (for patients without progression). Planning and delivery of locally advanced lung cancer radiotherapy usually should be performed using intensity-modulated radiotherapy techniques. A variety of palliative and radical fractionation schedules are available to treat patients with poor performance and/or pulmonary status. The salvage therapy for a local recurrence after successful primary management is complex and likely requires both multidisciplinary input and shared decision-making with the patient.Conclusions and RelevanceEvidence-based guidance on the management of various unresectable LA-NSCLC scenarios is provided by the ARS AUC to optimize multidisciplinary patient care for this challenging patient population.
重要性50多年来的临床试验和其他相关文献为局部晚期非小细胞肺癌(LA-NSCLC)的治疗提供了依据。证据回顾美国镭学会(ARS)适当使用标准(AUC)胸部委员会指南是一份循证共识文件,评估了与 LA-NSCLC 相关的各种临床情况。研究结果通过基于共识的改良德尔菲法对各种 LA-NSCLC 方案的治疗适宜性进行了评估,采用 3 分到 9 分的范围表示共识一致。委员会的建议由ARS AUC执行委员会审核,并在正式批准和通过前经过2周的公众评议期。预后良好的 LA-NSCLC 的标准治疗方法包括联合同期根治性(60-70 Gy)铂类化疗,然后进行巩固性 durvalumab 免疫治疗(适用于无进展的患者)。局部晚期肺癌放疗的计划和实施通常应采用调强放疗技术。有多种姑息性和根治性分次放疗方案可用于治疗表现不佳和/或肺部状况不佳的患者。初治成功后局部复发的挽救治疗非常复杂,可能需要多学科参与并与患者共同决策。结论与相关性ARS AUC为各种不可切除的LA-NSCLC的治疗提供了基于证据的指导,以优化这一具有挑战性的患者群体的多学科患者治疗。
{"title":"American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer","authors":"George Rodrigues, Kristin A. Higgins, Andreas Rimner, Arya Amini, Joe Y. Chang, Stephen G. Chun, Jessica Donington, Martin J. Edelman, Matthew A. Gubens, Puneeth Iyengar, Benjamin Movsas, Matthew S. Ning, Henry S. Park, Andrea Wolf, Charles B. Simone","doi":"10.1001/jamaoncol.2024.0294","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.0294","url":null,"abstract":"ImportanceThe treatment of locally advanced non–small cell lung cancer (LA-NSCLC) has been informed by more than 5 decades of clinical trials and other relevant literature. However, controversies remain regarding the application of various radiation and systemic therapies in commonly encountered clinical scenarios.ObjectiveTo develop case-referenced consensus and evidence-based guidelines to inform clinical practice in unresectable LA-NSCLC.Evidence ReviewThe American Radium Society (ARS) Appropriate Use Criteria (AUC) Thoracic Committee guideline is an evidence-based consensus document assessing various clinical scenarios associated with LA-NSCLC. A systematic review of the literature with evidence ratings was conducted to inform the appropriateness of treatment recommendations by the ARS AUC Thoracic Committee for the management of unresectable LA-NSCLC.FindingsTreatment appropriateness of a variety of LA-NSCLC scenarios was assessed by a consensus-based modified Delphi approach using a range of 3 points to 9 points to denote consensus agreement. Committee recommendations were vetted by the ARS AUC Executive Committee and a 2-week public comment period before official approval and adoption. Standard of care management of good prognosis LA-NSCLC consists of combined concurrent radical (60-70 Gy) platinum-based chemoradiation followed by consolidation durvalumab immunotherapy (for patients without progression). Planning and delivery of locally advanced lung cancer radiotherapy usually should be performed using intensity-modulated radiotherapy techniques. A variety of palliative and radical fractionation schedules are available to treat patients with poor performance and/or pulmonary status. The salvage therapy for a local recurrence after successful primary management is complex and likely requires both multidisciplinary input and shared decision-making with the patient.Conclusions and RelevanceEvidence-based guidance on the management of various unresectable LA-NSCLC scenarios is provided by the ARS AUC to optimize multidisciplinary patient care for this challenging patient population.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"72 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140547841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Magnetic Resonance Imaging in Prostate Cancer Screening 磁共振成像在前列腺癌筛查中的应用
IF 28.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-04-05 DOI: 10.1001/jamaoncol.2024.0734
Tamás Fazekas, Sung Ryul Shim, Giuseppe Basile, Michael Baboudjian, Tamás Kói, Mikolaj Przydacz, Mohammad Abufaraj, Guillaume Ploussard, Veeru Kasivisvanathan, Juan Gómez Rivas, Giorgio Gandaglia, Tibor Szarvas, Ivo G. Schoots, Roderick C. N. van den Bergh, Michael S. Leapman, Péter Nyirády, Shahrokh F. Shariat, Pawel Rajwa
ImportanceProstate magnetic resonance imaging (MRI) is increasingly integrated within the prostate cancer (PCa) early detection pathway.ObjectiveTo systematically evaluate the existing evidence regarding screening pathways incorporating MRI with targeted biopsy and assess their diagnostic value compared with prostate-specific antigen (PSA)–based screening with systematic biopsy strategies.Data SourcesPubMed/MEDLINE, Embase, Cochrane/Central, Scopus, and Web of Science (through May 2023).Study SelectionRandomized clinical trials and prospective cohort studies were eligible if they reported data on the diagnostic utility of prostate MRI in the setting of PCa screening.Data ExtractionNumber of screened individuals, biopsy indications, biopsies performed, clinically significant PCa (csPCa) defined as International Society of Urological Pathology (ISUP) grade 2 or higher, and insignificant (ISUP1) PCas detected were extracted.Main Outcomes and MeasuresThe primary outcome was csPCa detection rate. Secondary outcomes included clinical insignificant PCa detection rate, biopsy indication rates, and the positive predictive value for the detection of csPCa.Data SynthesisThe generalized mixed-effect approach with pooled odds ratios (ORs) and random-effect models was used to compare the MRI-based and PSA-only screening strategies. Separate analyses were performed based on the timing of MRI (primary/sequential after a PSA test) and cutoff (Prostate Imaging Reporting and Data System [PI-RADS] score ≥3 or ≥4) for biopsy indication.ResultsData were synthesized from 80 114 men from 12 studies. Compared with standard PSA-based screening, the MRI pathway (sequential screening, PI-RADS score ≥3 cutoff for biopsy) was associated with higher odds of csPCa when tests results were positive (OR, 4.15; 95% CI, 2.93-5.88; P ≤ .001), decreased odds of biopsies (OR, 0.28; 95% CI, 0.22-0.36; P ≤ .001), and insignificant cancers detected (OR, 0.34; 95% CI, 0.23-0.49; P = .002) without significant differences in the detection of csPCa (OR, 1.02; 95% CI, 0.75-1.37; P = .86). Implementing a PI-RADS score of 4 or greater threshold for biopsy selection was associated with a further reduction in the odds of detecting insignificant PCa (OR, 0.23; 95% CI, 0.05-0.97; P = .048) and biopsies performed (OR, 0.19; 95% CI, 0.09-0.38; P = .01) without differences in csPCa detection (OR, 0.85; 95% CI, 0.49-1.45; P = .22).Conclusion and relevanceThe results of this systematic review and meta-analysis suggest that integrating MRI in PCa screening pathways is associated with a reduced number of unnecessary biopsies and overdiagnosis of insignificant PCa while maintaining csPCa detection as compared with PSA-only screening.
重要性前列腺磁共振成像(MRI)越来越多地被纳入前列腺癌(PCa)早期检测途径中.目的系统评估有关结合磁共振成像和靶向活检的筛查途径的现有证据,并评估其与基于前列腺特异性抗原(PSA)的系统活检筛查策略相比的诊断价值.数据来源PubMed/MEDLINE、Embase、Cochrane/Central、Scopus和Web of Science(至2023年5月).研究选择随机临床试验和前瞻性队列研究,只要报告了前列腺MRI在PCa筛查中的诊断效用的数据,均符合条件。数据提取提取了筛查人数、活检适应症、所做活检、有临床意义的PCa(csPCa)(定义为国际泌尿病理学会(ISUP)2级或更高级别)以及检测出的无临床意义的PCa(ISUP1)。次要结果包括临床不显著 PCa 检出率、活检适应症率和 csPCa 检出的阳性预测值。数据合成采用集合赔率比 (OR) 和随机效应模型的广义混合效应方法来比较基于 MRI 和仅 PSA 的筛查策略。根据核磁共振成像的时间(主要/PSA检测后的后续)和活检指征的临界值(前列腺成像报告和数据系统[PI-RADS]评分≥3或≥4)分别进行了分析。与基于 PSA 的标准筛查相比,MRI 途径(顺序筛查,PI-RADS 评分≥3 时为活组织检查临界值)在检测结果呈阳性时与较高的 csPCa 发生几率相关(OR,4.15;95% CI,2.93-5.88;P ≤ .001)、活检几率降低(OR,0.28;95% CI,0.22-0.36;P ≤ .001)、检测出的癌症不明显(OR,0.34;95% CI,0.23-0.49;P = .002),但在检测出 csPCa 方面无显著差异(OR,1.02;95% CI,0.75-1.37;P = .86)。实施 PI-RADS 评分 4 分或更高的活检选择阈值可进一步降低检测到不明显 PCa 的几率(OR,0.23;95% CI,0.05-0.97;P = .048)和活检率(OR,0.19;95% CI,0.09-0.38;P = .01),但 csPCa 的检测率没有差异(OR,0.85;95% CI,0.结论和相关性本系统综述和荟萃分析的结果表明,与单纯 PSA 筛查相比,将 MRI 纳入 PCa 筛查途径可减少不必要的活检次数和不明显 PCa 的过度诊断,同时保持 csPCa 的检出率。
{"title":"Magnetic Resonance Imaging in Prostate Cancer Screening","authors":"Tamás Fazekas, Sung Ryul Shim, Giuseppe Basile, Michael Baboudjian, Tamás Kói, Mikolaj Przydacz, Mohammad Abufaraj, Guillaume Ploussard, Veeru Kasivisvanathan, Juan Gómez Rivas, Giorgio Gandaglia, Tibor Szarvas, Ivo G. Schoots, Roderick C. N. van den Bergh, Michael S. Leapman, Péter Nyirády, Shahrokh F. Shariat, Pawel Rajwa","doi":"10.1001/jamaoncol.2024.0734","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.0734","url":null,"abstract":"ImportanceProstate magnetic resonance imaging (MRI) is increasingly integrated within the prostate cancer (PCa) early detection pathway.ObjectiveTo systematically evaluate the existing evidence regarding screening pathways incorporating MRI with targeted biopsy and assess their diagnostic value compared with prostate-specific antigen (PSA)–based screening with systematic biopsy strategies.Data SourcesPubMed/MEDLINE, Embase, Cochrane/Central, Scopus, and Web of Science (through May 2023).Study SelectionRandomized clinical trials and prospective cohort studies were eligible if they reported data on the diagnostic utility of prostate MRI in the setting of PCa screening.Data ExtractionNumber of screened individuals, biopsy indications, biopsies performed, clinically significant PCa (csPCa) defined as International Society of Urological Pathology (ISUP) grade 2 or higher, and insignificant (ISUP1) PCas detected were extracted.Main Outcomes and MeasuresThe primary outcome was csPCa detection rate. Secondary outcomes included clinical insignificant PCa detection rate, biopsy indication rates, and the positive predictive value for the detection of csPCa.Data SynthesisThe generalized mixed-effect approach with pooled odds ratios (ORs) and random-effect models was used to compare the MRI-based and PSA-only screening strategies. Separate analyses were performed based on the timing of MRI (primary/sequential after a PSA test) and cutoff (Prostate Imaging Reporting and Data System [PI-RADS] score ≥3 or ≥4) for biopsy indication.ResultsData were synthesized from 80 114 men from 12 studies. Compared with standard PSA-based screening, the MRI pathway (sequential screening, PI-RADS score ≥3 cutoff for biopsy) was associated with higher odds of csPCa when tests results were positive (OR, 4.15; 95% CI, 2.93-5.88; <jats:italic>P</jats:italic> ≤ .001), decreased odds of biopsies (OR, 0.28; 95% CI, 0.22-0.36; <jats:italic>P</jats:italic> ≤ .001), and insignificant cancers detected (OR, 0.34; 95% CI, 0.23-0.49; <jats:italic>P</jats:italic> = .002) without significant differences in the detection of csPCa (OR, 1.02; 95% CI, 0.75-1.37; <jats:italic>P</jats:italic> = .86). Implementing a PI-RADS score of 4 or greater threshold for biopsy selection was associated with a further reduction in the odds of detecting insignificant PCa (OR, 0.23; 95% CI, 0.05-0.97; <jats:italic>P</jats:italic> = .048) and biopsies performed (OR, 0.19; 95% CI, 0.09-0.38; <jats:italic>P</jats:italic> = .01) without differences in csPCa detection (OR, 0.85; 95% CI, 0.49-1.45; <jats:italic>P</jats:italic> = .22).Conclusion and relevanceThe results of this systematic review and meta-analysis suggest that integrating MRI in PCa screening pathways is associated with a reduced number of unnecessary biopsies and overdiagnosis of insignificant PCa while maintaining csPCa detection as compared with PSA-only screening.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"127 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140352317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ovarian Cancer Isn’t Just a White Woman’s Disease 卵巢癌不仅仅是白人女性的疾病
IF 28.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-04-04 DOI: 10.1001/jamaoncol.2024.0191
Anna Jo Bodurtha Smith, Elizabeth A. Howell, Emily M. Ko
This Viewpoint highlights the need for recognition that ovarian cancer affects women from racial and ethnic minority groups worldwide and that the rates of ovarian cancer are increasing in those populations while decreasing among White women.
本观点强调有必要认识到卵巢癌影响着全世界少数种族和族裔群体的妇女,而且这些人群的卵巢癌发病率正在上升,而白人妇女的发病率却在下降。
{"title":"Ovarian Cancer Isn’t Just a White Woman’s Disease","authors":"Anna Jo Bodurtha Smith, Elizabeth A. Howell, Emily M. Ko","doi":"10.1001/jamaoncol.2024.0191","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.0191","url":null,"abstract":"This Viewpoint highlights the need for recognition that ovarian cancer affects women from racial and ethnic minority groups worldwide and that the rates of ovarian cancer are increasing in those populations while decreasing among White women.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"257 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140349207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAMA Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1